Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults.
Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | -0.54 Increased by +32.50% | -0.48 Decreased by -12.50% |
| Mar 12, 24 | -0.66 Increased by +33.33% | -0.24 Decreased by -175.00% |
| Nov 2, 23 | -0.57 Increased by +44.12% | -0.63 Increased by +9.52% |
| Aug 3, 23 | -1.94 Decreased by -130.95% | -0.80 Decreased by -142.50% |
| May 4, 23 | -0.80 Increased by +31.62% | -0.94 Increased by +14.89% |
| Mar 8, 23 | -0.99 Increased by +40.36% | -1.02 Increased by +2.94% |
| Nov 9, 22 | -1.02 Increased by +34.19% | -1.07 Increased by +4.67% |
| Aug 4, 22 | -0.84 Increased by +42.07% | -1.15 Increased by +26.96% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 47.73 M Increased by +154.13% | -23.59 M Increased by +33.94% | Decreased by -49.42% Increased by +74.00% |
| Jun 30, 23 | 37.50 M Increased by +114.46% | -74.04 M Decreased by -175.01% | Decreased by -197.45% Decreased by -28.23% |
| Mar 31, 23 | 31.60 M Increased by +145.10% | -30.13 M Increased by +17.69% | Decreased by -95.35% Increased by +66.42% |
| Dec 31, 22 | 27.91 M Increased by +789.29% | -36.43 M Decreased by -163.31% | Decreased by -130.55% Decreased by -107.12% |
| Sep 30, 22 | 18.78 M Increased by +275.60% | -35.71 M Increased by +24.20% | Decreased by -190.13% Increased by +79.82% |
| Jun 30, 22 | 17.48 M Increased by +58.95% | -26.92 M Increased by +38.67% | Decreased by -153.98% Increased by +61.41% |
| Mar 31, 22 | 12.89 M Increased by +N/A% | -36.61 M Increased by +27.56% | Decreased by -283.94% Decreased by N/A% |
| Dec 31, 21 | 3.14 M Increased by +N/A% | 57.55 M Increased by +254.68% | Increased by +1.83 K% Decreased by N/A% |